Associated Papers
Novel druggable space in human KRAS G13D discovered using structural bioinformatics and a P-loop targeting monoclonal antibody.
Jungholm O et al.
Scientific Reports, 2024
39179604 (PubMed )
Supplement: 41598_2024_70217_MOESM1_ESM.docx
RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status.
Dorard C et al.
Oncogene, 2023
37020037 (PubMed )
Supplement: 41388_2023_2683_MOESM1_ESM.pdf
Molecular pathways in periampullary cancer: An overview.
Apurva et al.
Cellular Signalling, 2022
The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological processes to therapeutic targeting.
Jonckheere N et al.
Critical Reviews in Oncology/hematology, 2017
Ratio of Autoantibodies of Tumor Suppressor AIMP2 and Its Oncogenic Variant Is Associated with Clinical Outcome in Lung Cancer.
Jung JY et al.
Journal of Cancer, 2017
Selection for Evi1 activation in myelomonocytic leukemia induced by hyperactive signaling through wild-type NRas.
Wolf S et al.
Oncogene, 2013
PRAK suppresses oncogenic ras-induced hematopoietic cancer development by antagonizing the JNK pathway.
Yoshizuka N et al.
Molecular Cancer Research : Mcr, 2012
Exploiting the origins of Ras mediated squamous cell carcinoma to develop novel therapeutic interventions.
White AC et al.
Small Gtpases, 2011
Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy.
Gattenlöhner S et al.
Journal of Oncology, 2009
Select a paper to view details